Back to discover
Disease

Alopecia Areata

Late-stage therapeutic developmentEmerging research
MeSHAlopecia Areata
2
Publications
19
Clinical trials
12
Associated genes
2
Related proteins
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Pilot Study on Intralesional Cyclosporine for Alopecia Areata

Clinical trial2026-08-06Status changed to Active, not recruiting · ClinicalTrials.gov

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss

Clinical trial2026-07-30Status changed to Active, not recruiting · ClinicalTrials.gov

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q4 2027.
  • 2 industry developments reported.
Upcoming Milestones
Clinical Milestones10View all 10
Results posted 3
Results expected 5
Other updates 1
+2 more in the activity timeline below
Industry & Market2View
Activity timeline12

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Baricitinibapproved

Approval — Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe ac… (2017)

Clinical trials

14 sponsors · 2 new · 1 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
14
Late-stage
6
Completed
Late-stage studies

A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Phase 3 · Recruiting · Pfizer

A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata

Phase 3 · Recruiting · AbbVie

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss

Phase 3 · Active, not recruiting · AbbVie

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period

Phase 3 · Recruiting · Sun Pharma Japan Limited

A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period

Phase 3 · Recruiting · Sun Pharmaceutical Industries, Inc.

A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

Phase 3 · Completed · Pfizer
Recruiting

A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Phase 3 · Recruiting · Pfizer

A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata

Phase 3 · Recruiting · AbbVie

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period

Phase 3 · Recruiting · Sun Pharma Japan Limited

A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period

Phase 3 · Recruiting · Sun Pharmaceutical Industries, Inc.

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participants and Severe Alopecia Areata Trial Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Study

Phase 1 · Recruiting · Innovent Biologics (Suzhou) Co. Ltd.
Recently completed

Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata: A Randomized Controlled Trial.

Phase 4 · Completed · Cairo University

A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Phase 3 · Completed · Sun Pharmaceutical Industries, Inc.

A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata

Phase 3 · Completed · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

Phase 3 · Completed · Pfizer

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

Phase 3 · Completed · Jinnah Hospital

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

Phase 2/3 · Completed · Eli Lilly and Company

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2017emaApproval — Baricitinib· Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate. Atopic Dermatitis Olumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. Alopecia areata Baricitinib is indicated for the treatment of severe alopecia areata in adult and adolescent patients 12 years of age and older.  Juvenile idiopathic arthritis Baricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs: Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), Enthesitis related arthritis, and Juvenile psoriatic arthritis. Baricitinib may be used as monotherapy or in combination with methotrexate. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20192020
Most influential

Hair follicle immune privilege and its collapse in alopecia areata.

Experimental dermatology · 2020 · 194 cites

Frontiers in alopecia areata pathobiology research.

The Journal of allergy and clinical immunology · 2019 · 66 cites
Recent publications

Hair follicle immune privilege and its collapse in alopecia areata.

Experimental dermatology · 2020 · 194 cites

Frontiers in alopecia areata pathobiology research.

The Journal of allergy and clinical immunology · 2019 · 66 cites
Major themes2
  • Immune Privilege1
  • Immunity, Innate1
Leading journals2
  • Experimental dermatology1
  • The Journal of allergy and clinical immunology1
Leading researchers7
  • Gilhar A2
  • Paus R2
  • Bertolini M1
  • Bulfone-Paus S1
  • Keren A1
  • Laufer-Britva R1
  • McElwee K1
Affiliations (unnormalised)6
  • Centre for Dermatology Research1
  • Centre for Skin Sciences1
  • Laboratory for Skin Research1
  • Miller School of Medicine1
  • Monasterium Laboratory1
  • Skin Research Laboratory1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

JAK30.57BTK0.56GRXCR10.34GTF3C10.34RAET1L0.33FER0.33SLC24A20.32SLC7A110.32ADGB0.31SENP20.31NDST30.31BCL2L140.30

Disease biology

2 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Tyrosine-protein kinase JAK3via JAK30.57Tyrosine-protein kinase BTKvia BTK0.56

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Loss of scalp and body hair involving microscopically inflammatory patchy areas.

Identifiers
MeSHAlopecia Areata
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.